Skip to content
OpenCapital
Get started

Fulgent Genetics, Inc. FLGT Q1 2026 earnings

Reported May 1, 2026 · Before market open

Revenue$71.1MBeat by $3.0M
EPS-$0.36Miss by $0.01
Revenue estimate$68.1M
EPS estimate-$0.35

Next report

Jul 30, 2026 (Tomorrow)
Revenue estimate$94.0M
EPS estimate-$0.46

Financials

Q1 2026

Income statement

See full
Revenue$71.1M-3.2%
Gross profit$21.5M-24.2%
Operating income-$34.6M-74.9%
Net income-$24.8M-115%
EPS (diluted)-$0.80-116%

Balance sheet

See full
Cash & equivalents$23.4M-65.2%
Total debt$8.2M+40.5%
Total equity$1.0B-6.9%
Total assets$1.2B-4.1%

Cash flow

See full
Operating cash flow$7.1M+260%
CapEx$5.2M+10.3%
Free cash flow$1.9M+121%

Valuation & ratios

Valuation

as of 07/28/26
See full
Market cap$556.08M+1.4%
Enterprise value$540.9M+16.0%
P/S1.7×-0.1×

Profitability

See full
Gross margin38.7%-0.1pp
Operating margin-33.1%+17.4pp
Net margin-23%+43.3pp
FCF margin-36.9%—

Returns & leverage

See full
Return on equity-6.8%+48.2pp
Debt / equity0×0.0×
Current ratio5.3×-1.0×

Segments

By segment

See full
Laboratory Services$71.1M-3.3%
Therapeutic Development$87.0K—

By geography

See full
Non Us$6.0M+7.0%
Other Countries$3.5M+14.8%

Versus estimates

Revenue

Q1 2026$71.1MBeat by $3.0M
Q4 2025$83.3MMiss by $2.0MQ3 2025$84.1MMiss by $1.3MQ2 2025$81.8MBeat by $373.0KQ1 2025$73.5MMiss by $3.5MQ4 2024$76.2MBeat by $821.4K

Diluted EPS

Q1 2026-$0.36Miss by $0.01
Q4 2025$0.16Beat by $0.13Q3 2025$0.14Beat by $0.38Q2 2025$0.07Beat by $0.30Q1 2025$0.04Beat by $0.23Q4 2024$0.04Beat by $0.35

Ask the moment Fulgent Genetics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Fulgent Genetics, Inc. report Q1 2026 earnings?
Fulgent Genetics, Inc. (FLGT) reported Q1 2026 earnings on May 1, 2026 before market open.
What were Fulgent Genetics, Inc.'s Q1 2026 revenue and EPS?
Fulgent Genetics, Inc. reported revenue of $71.1M and eps of $-0.36 for Q1 2026.
Did Fulgent Genetics, Inc. beat estimates in Q1 2026?
Revenue beat the consensus estimate of $68.1M by $3.0M. EPS missed the consensus estimate of $-0.35 by $0.01.
How did Fulgent Genetics, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 3.2% from $73.5M a year earlier.
Where can I find Fulgent Genetics, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-199061) and the 10-Q periodic report (0001193125-26-199065) directly on SEC EDGAR. The filing index links above go to sec.gov.